Aandeel NBIX NEUROCRINE BIOSCIENCES, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Neurocrine Biosciences, Inc.

Aandelen

NBIX

US64125C1099

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
136 USD -1,28% Intraday-grafiek van Neurocrine Biosciences, Inc. +3,02% +3,21%
24/04 NEUROCRINE BIOSCIENCES, INC. : Wells Fargo Securities verhoogt advies van Neutraal naar Kopen ZM
24/04 Neurocrine Biosciences, Inc. lanceert Wat de C@H! voorlichtingsinitiatief om de gemeenschap van aangeboren bijnierhyperplasie te ondersteunen CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Neurocrine Biosciences Launches WHAT THE C@H Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Investor Conferences in March
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers NBIX
  4. Nieuws Neurocrine Biosciences, Inc.
  5. Andere talen